文献速递乳腺癌

金龙胶囊联合新辅助化疗对浸润性乳腺癌的疗效及多药耐药蛋白表达变化

[Therapeutic effect of Jin Long capsule combined with neoadjuvant chemotherapy on invasive breast cancer and the expression change of multidrug resistance proteins].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2019-01-01

200例浸润性乳腺癌患者分为试验组和对照组各100例,对照组采用TEC方案新辅助化疗,试验组加用金龙胶囊口服。试验组有效率为83.0%,高于对照组的65.0%(P<0.05);试验组3~4级白细胞减少、胃肠道反应和脱发发生率均低于对照组(均P<0.05)。

要点

  • 金龙胶囊联合TEC方案新辅助化疗组有效率为83.0%,高于对照组的65.0%(P<0.05)。
  • 试验组3~4级白细胞减少、胃肠道反应和脱发发生率均低于对照组(均P<0.05)。
  • 对照组化疗后P-gp和GST-π阳性率及表达强度升高、TopoⅡα降低(均P<0.05),试验组化疗前后无显著差异(均P>0.05)。

核心结论

  • 金龙胶囊可抑制多药耐药,提高乳腺癌新辅助化疗疗效,降低不良反应。

研究设计与样本

  • 将200例患者按新辅助治疗方法分为试验组和对照组,每组100例。
  • 对照组采用TEC方案(多西他赛+表柔比星+环磷酰胺)新辅助化疗,试验组化疗方案同对照组并给予金龙胶囊口服。
  • 参照Miller & Payne分级系统(MP)依据新辅助化疗后乳腺癌病理组织学改变评价疗效。
  • 按照美国国家癌症研究所常见不良反应事件评价标准(CTCAE)3.0版分级标准评价不良反应。
  • 采用免疫组织化学方法检测治疗前后乳腺癌组织中P-糖蛋白(P-gp)、谷胱苷肽巯基转移酶(GST)-π和拓扑异构酶Ⅱα(TopoⅡα)的表达。

主要发现

  • 试验组83例有效,有效率为83.0%,高于对照组的65.0%(P<0.05)。
  • 试验组3~4级白细胞减少、胃肠道反应和脱发的发生率均低于对照组(均P<0.05)。
  • 对照组化疗前P-gp、GST-π和TopoⅡα表达阳性率分别为65.0%(65/100)、61.0%(61/100)和69.0%(69/100),化疗后分别为80.6%(75/93)、78.5%(73/93)和37.6%(35/93)。
  • 对照组化疗后P-gp和GST-π表达阳性率均明显高于化疗前(均P<0.05),TopoⅡα表达阳性率明显低于化疗前(P<0.05);对照组化疗后P-gp和GST-π表达强度增高、TopoⅡα表达强度降低(均P<0.05)。
  • 试验组化疗前P-gp、GST-π和TopoⅡα表达阳性率分别为62.0%(62/100)、63.0%(63/100)和69.0%(69/100),化疗后分别为68.2%(60/88)、67.0%(59/88)和63.6%(56/88),化疗前后表达阳性率和表达强度差异均无统计学意义(均P>0.05)。

临床怎么用

  • 作者认为金龙胶囊可抑制乳腺癌多药耐药,提高新辅助化疗疗效并降低不良反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the therapeutic effect of Jin Long Capsule (JLC) combined with neoadjuvant chemotherapy on the invasive breast cancer, and to explore the mechanism of JLC in inhibiting multidrug resistance of breast cancer. Methods: 200 patients were divided into experimental group and control group (100 cases per group). The control group used TEC regimen for neoadjuvant chemotherapy. And the experimental group was treated with TEC regimen combined with oral JLC. According to the Miller & Payne grading system (MP), the efficacy of neoadjuvant chemotherapy was evaluated based on histopathological changes of breast cancer after neoadjuvant chemotherapy. Adverse effect was evaluated according to the classification criteria of the National Cancer Institute of the United States-The Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The expression of P-glycoprotein (P-gp), glutathione thiol transferase (GST)-π and topoisomerase Ⅱα (TopoⅡα) in breast cancer tissues before and after neoadjuvant chemotherapy were detected by immunohistochemical staining. Results: There were 83 effective cases (83%) in the experimental group, which was higher than that in the control group (65.0%, P<0.05). The incidence of leukopenia, gastrointestinal reactions and alopecia in grade 3 to 4 of the experimental group were lower than those of the control group (all P<0.05). The positive rates of P-gp, GST-π and TopoⅡα expression in the control group were 65.0% (65/100), 61.0% (61/100) and 69.0% (69/100), respectively, and they were 80.6% (75/93), 78.5% (73/93) and 37.6% (35/93) after chemotherapy. The positive rates of P-gp and GST-π expression were significantly higher than those before chemotherapy (both P<0.05), whereas the positive rate of TopoⅡα expression was significantly lower than that before chemotherapy (P<0.05). In the experimental group, the positive rates of P-gp, GST-π and TopoⅡα expression before chemotherapy were 62.0% (62/100), 63.0% (63/100) and 69.0% (69/100), respectively, while after chemotherapy, they were 68.2% (60/88), 67.0% (59/88) and 63.6% (56/88). There was no significant difference in the positive rates and expression intensity of P-gp, GST-π and TopoⅡα before and after the chemotherapy (P>0.05). Conclusion: Jin Long Capsule (JLC) can inhibit multidrug resistance, improve the efficacy of neoadjuvant chemotherapy, and reduce adverse reactions of breast cancer. 目的: 观察金龙胶囊联合新辅助化疗治疗乳腺癌的疗效,探讨金龙胶囊抑制乳腺癌多药耐药的机制。 方法: 将200例患者按新辅助治疗方法分为试验组和对照组,每组100例。对照组采用TEC方案(多西他赛+表柔比星+环磷酰胺)进行新辅助化疗,试验组化疗方案同对照组,同时给予金龙胶囊口服。参照Miller & Payne分级系统(MP),依据新辅助化疗后乳腺癌病理组织学改变评价新辅助化疗疗效。按照美国国家癌症研究所常见不良反应事件评价标准(CTCAE)3.0版的分级标准评价不良反应。采用免疫组织化学方法检测治疗前后乳腺癌组织中P-糖蛋白(P-gp)、谷胱苷肽巯基转移酶(GST)-π和拓扑异构酶Ⅱα(TopoⅡα)的表达。 结果: 试验组83例有效,有效率为83.0%,高于对照组的65.0%(P<0.05)。试验组3~4级白细胞减少、胃肠道反应和脱发的发生率均低于对照组(均P<0.05)。对照组患者化疗前P-gp、GST-π和TopoⅡα表达阳性率分别为65.0%(65/100)、61.0%(61/100)和69.0%(69/100),化疗后分别为80.6%(75/93)、78.5%(73/93)和37.6%(35/93),P-gp和GST-π表达阳性率化疗后均明显高于化疗前(均P<0.05),TopoⅡα表达阳性率化疗后明显低于化疗前(P<0.05)。对照组患者化疗后P-gp和GST-π表达强度增高,TopoⅡα的表达强度降低,差异均有统计学意义(均P<0.05)。试验组患者化疗前P-gp、GST-π和TopoⅡα表达阳性率分别为62.0%(62/100)、63.0%(63/100)和69.0%(69/100),化疗后分别为68.2%(60/88)、67.0%(59/88)和63.6%(56/88),试验组患者化疗前后P-gp、GST-π和TopoⅡα的表达阳性率和表达强度差异均无统计学意义(均P>0.05)。 结论: 金龙胶囊可抑制乳腺癌的多药耐药,能提高乳腺癌新辅助化疗疗效,降低不良反应。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang TY, Yi W, Wen J, et al. [Therapeutic effect of Jin Long capsule combined with neoadjuvant chemotherapy on invasive breast cancer and the expression change of multidrug resistance proteins]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 30862141. doi:10.3760/cma.j.issn.0253-3766.2019.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。